Examining the Impact of the World Health Organization 2022 Guidelines on Evaluation of Biosimilars for Non-Local Comparators in Biosimilar Studies on Middle East and North Africa Member States

Author:

Strand Michael W.1,Watanabe Jonathan H.1ORCID

Affiliation:

1. Center for Data-Driven Drugs Research and Policy, School of Pharmacy and Pharmaceutical Sciences, University of California, 856 Health Sciences Drive Road, Irvine, CA 92697, USA

Abstract

Global support and standardization of regulation for biosimilars approval owes much of its legacy to the World Health Organization (WHO), since the first guidance by the organization on the matter was released in 2009. Since then, and with over a decade of research, the 2022 revision provides opportunities for time and financial savings to pharmaceutical manufacturers aiming to prove similarity of a potential biosimilar product to some reference product, particularly by clarifying that the use of a non-local reference product as a comparator in certain studies is permissible. This declaration has important implications, particularly in the emerging biological markets of the Middle East and North Africa region, where WHO guidelines have been integral to the regulatory framework of over a dozen countries for more than a decade. This article aims to review the impact of this revision on these countries and relevant policies on non-local comparator usage. Since 2022, this revision has been adopted only in Egypt. Many North African countries are yet to adopt a first draft of the formalized guidance. This analysis revealed that, although many of these countries reference the WHO guidelines, hesitation remains in terms of sourcing comparator products outside the US or European countries. This likely translates to slow regional development and cooperation of functioning, sustainable biosimilars markets. Future studies will be necessary to evaluate the continued development of guidance within these countries and changes in comparator sourcing norms as more time is allowed for their policies to mature and adapt to new standards.

Publisher

MDPI AG

Reference31 articles.

1. (2024, March 27). Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs), Annex 2, TRS No 977. Available online: https://www.who.int/publications/m/item/sbp-trs-977-Annex-2.

2. The Regulatory Landscape of Biosimilars: WHO Efforts and Progress Made from 2009 to 2019;Kang;Biologicals,2020

3. The Status and Preparation for the next Decade of Biosimilars in the Middle Eastern and North African Region;Alkhatib;Expert Opin. Biol. Ther.,2023

4. Regulatory Considerations in Biosimilars: Middle East and Africa Regions;Rathore;Prep. Biochem. Biotechnol.,2021

5. Potential for Biosimilars in Rheumatology in Africa;Adebajo;Ann. Rheum. Dis.,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3